Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
121-140 of 998 trials

Limb Girdle Muscular Dystrophy 2E/R4: SRP-9003 Gene Therapy

We are studying a new gene therapy to see if it improves muscle function in people with Limb Girdle Muscular Dystrophy 2E/R4. The trial will evaluate its safety and effectiveness over time.

Limb-girdle Muscular Dystrophy Type 2E/R4>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Chronic Hypoparathyroidism: Eneboparatide (AZP-3601)

We are studying a new medication to see if it helps people with chronic hypoparathyroidism manage their calcium levels and improve their physical symptoms. This trial compares the new treatment to a placebo to assess its effectiveness.

Hypoparathyroidism6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Recurrent Solid Tumors: IMA402 Treatment Study

We are testing a new treatment called IMA402 for patients with recurrent or hard-to-treat solid tumors. The study aims to evaluate its safety and how well it works, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Recurrent Miscarriages: PREMI Trial on Prednisolone

We are studying whether prednisolone can help women with unexplained recurrent miscarriages achieve a live birth. The trial compares this treatment to a placebo and looks at pregnancy outcomes and safety.

Recurrent Miscarriages1-2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tislelizumab for Cancer Patients with Residual Disease

We are studying whether tislelizumab can help cancer patients who still have detectable disease after standard treatment. The goal is to see if it improves their chances of staying cancer-free compared to a placebo.

Pancreatic CancerSoft Tissue SarcomaNon-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteGastroenterologyOncologyPulmonology

Menière's Disease: Methylprednisolone Injection Study

We are investigating whether an injection of methylprednisolone can reduce vertigo attacks in patients with Menière's disease. This study will also assess its effects on hearing and overall quality of life.

Menière's Disease1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteOtolaryngology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology